FDA Approved: EVENITY — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for Evenity (romosozumab-aqqg) from Amgen, reflecting regulatory approval based on the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Evenity (romosozumab)

Snippet

SUPPL AP for EVENITY (ROMOSOZUMAB-AQQG)